VivoSeq
Other

Radiotherapy

0

Pipeline Programs↗

35

Active Trials↗

11

Companies Involved↗

Radiotherapy is an early-stage landscape with 0 programs across 11 companies. The most active players are EMD Serono Research & Development Institute, Inc., Trans Tasman Radiation Oncology Group, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

32/100

Mech. Concentration

N/A

Completion Rate

61/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

PreclinicalT

Trans Tasman Radiation Oncology Group

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalJ

Johnson & Johnson Taiwan Ltd

0 programs

PreclinicalL

Lipomedix Pharmaceuticals Inc.

0 programs

PreclinicalQilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

127

clinical trials

Completed41 · 32%
Unknown status25 · 20%
Terminated20 · 16%
Recruiting16 · 13%
Not yet recruiting13 · 10%
Active, not recruiting6 · 5%
Other6 · 5%

Clinical Trials

Trial Activity

127 trials

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06472037·30 enrolled
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Recruiting·—·Phase 3·NCT07186621·286 enrolled
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06477692·80 enrolled
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Recruiting·—·Phase 2·NCT07165847·40 enrolled
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
Recruiting·—·Phase 2·NCT07210086·50 enrolled
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Recruiting·Children's Oncology Group·Phase 2·NCT06368817·240 enrolled
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Recruiting·—·Phase 2·NCT02128906·120 enrolled
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT05514275·41 enrolled
PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Recruiting·UUniversity Health Network, Toronto·N/A·NCT04901884·40 enrolled
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Recruiting·UUniversity of Leeds·Phase 1·NCT04550104·200 enrolled
Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06734598·120 enrolled
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Recruiting·JJIANYANG WANG·Phase 2·NCT07037680·44 enrolled
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Recruiting·—·Phase 2·NCT06999707·45 enrolled
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Recruiting·MMelanoma Institute Australia·Phase 2·NCT03340129·218 enrolled
Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease
Recruiting·BBaptist Health South Florida·Phase 1/2·NCT05534321·74 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)